openPR Logo
Press release

Patient-Derived Xenograft/PDX Model Market worth $574.99 million by 2030, growing at a CAGR of 14.54% - Exclusive Report by 360iResearch

02-23-2024 06:25 AM CET | Health & Medicine

Press release from: 360iResearch

Patient-Derived Xenograft/PDX Model Market | 360iResearch

Patient-Derived Xenograft/PDX Model Market | 360iResearch

The "Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.

The Global Patient-Derived Xenograft/PDX Model Market to grow from USD 222.26 million in 2023 to USD 574.99 million by 2030, at a CAGR of 14.54%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/patient-derived-xenograft-pdx-model?utm_source=openpr&utm_medium=referral&utm_campaign=sample

A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.

The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region's investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.

Market Segmentation & Coverage:

This research report categorizes the Patient-Derived Xenograft/PDX Model Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Mice Models and Rat Models. The Mice Models is projected to witness significant market share during forecast period.

Based on Tumor Type, market is studied across Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models, Respiratory Tumor Models, and Urological Tumor Models. The Respiratory Tumor Models is projected to witness significant market share during forecast period.

Based on Application, market is studied across Basic Cancer Research, Biomarker Analysis, and Preclinical Drug Development. The Basic Cancer Research is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Academic & Research Institutions, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies. The Academic & Research Institutions is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.41% in 2023, followed by Europe, Middle East & Africa.

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/patient-derived-xenograft-pdx-model?utm_source=openpr&utm_medium=referral&utm_campaign=inquire

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Patient-Derived Xenograft/PDX Model Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Patient-Derived Xenograft/PDX Model Market, by Type
7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type
8. Patient-Derived Xenograft/PDX Model Market, by Application
9. Patient-Derived Xenograft/PDX Model Market, by End-User
10. Americas Patient-Derived Xenograft/PDX Model Market
11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market
12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market
13. Competitive Landscape
14. Competitive Portfolio

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Patient-Derived Xenograft/PDX Model Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Patient-Derived Xenograft/PDX Model Market?
3. What is the competitive strategic window for opportunities in the Patient-Derived Xenograft/PDX Model Market?
4. What are the technology trends and regulatory frameworks in the Patient-Derived Xenograft/PDX Model Market?
5. What is the market share of the leading vendors in the Patient-Derived Xenograft/PDX Model Market?
6. What modes and strategic moves are considered suitable for entering the Patient-Derived Xenograft/PDX Model Market?

Read More @ https://www.360iresearch.com/library/intelligence/patient-derived-xenograft-pdx-model?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Patient-Derived Xenograft/PDX Model Market worth $574.99 million by 2030, growing at a CAGR of 14.54% - Exclusive Report by 360iResearch here

News-ID: 3396242 • Views:

More Releases from 360iResearch

Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Global Treatment Demand
Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Globa …
In recent years, the silent ascent of human metapneumovirus (HMPV) infections has begun to capture significant attention within the realm of infectious diseases. As we advance in medical science, unraveling complexities of age-old pathogens like common influenza or emerging illnesses like COVID-19, a critical discourse has been emerging around HMPV. Particularly, there seems to be a burgeoning acknowledgment of its growing impact on vulnerable global populations, propelling an increased demand
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and expected to reach USD 10.06 billion in 2024, at a CAGR 7.63% to reach USD 15.71 billion by 2030.
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and …
From Appetite to Advocacy: The Rising Demand for Meat Alternatives In recent years, the global food industry has been undergoing a remarkable transformation, driven primarily by an increasing consumer demand for healthier, sustainable, and ethically sourced food products. This seismic shift has brought traditional meat alternatives and high-protein plant-based foods into the spotlight. As the world becomes more conscious of the implications of meat consumption on health and the environment, the
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 2023 and expected to reach USD 292.84 billion in 2024, at a CAGR 11.08% to reach USD 552.63 billion by 2030.
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 202 …
Unpacking the Surge in Investments and Collaborations to Bolster Mobility-as-a-Service In recent years, as urban landscapes continually evolve, a transformative shift known as Mobility-as-a-Service (MaaS) has reshaped the way we perceive transportation. Marked by the integration of various forms of transport services into a single accessible on-demand mobility solution, MaaS is rapidly gaining traction across global cities. As an emerging paradigm, it's not just shaping the future of travel but also
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 and expected to reach USD 62.23 billion in 2024, at a CAGR 9.99% to reach USD 110.34 billion by 2030.
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 …
Smart City Revolutions: Why Data Center Colocation is the Future Backbone In the era of digital transformation, urban landscapes across the globe are undergoing a seismic shift toward becoming "smart cities." The concept of a smart city revolves around using digital technology, IoT (Internet of Things), AI, and data analytics at an unprecedented scale to improve urban infrastructure, manage resources efficiently, and enhance the quality of life for citizens. A vital

All 5 Releases


More Releases for Model

Animal Model Market
The Global Animal Model Market, detailed in the TechSci Research report titled, "Animal Model Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028," exhibited a value of USD 1.67 billion in 2022, poised to grow at a Compound Annual Growth Rate (CAGR) of 7.64% from 2024 to 2028. This comprehensive analysis delves into the intricate web of factors driving the market, including the global burden of chronic
Executing a Business Model Transformation with A Business Model Canvas
Business model transformation is the process of changing the way a company operates, with the aim of improving its overall performance. This transformation often involves significant changes to a company's existing business model. To ensure that the transformation process is successful, companies can use a tool called the business model canvas. Get a free business model canvas here: https://digitalleadership.com/unite-articles/extended-business-model-canvas/ Steps in Executing a Business Model Transformation with A Business Model Canvas Business
Fourth Party Logistics Market : Industry Innovator Model, Solution Integrator Mo …
The fourth party logistics market was valued at $57.9 billion in 2021, and is estimated to reach $111.7 billion by 2031, growing at a CAGR of 6.7% from 2022 to 2031. Fourth party logistics, popularly known as 4PL, is the model of outsourcing of logistics operations, where the service provider integrates with the company's supply chain department. This logistics partner is responsible for assessing, designing, building, running, and measuring integrated supply
How Drizly Works: Business Model & Revenue Model
‘Slow and steady wins the race.’ Such is the case with the world’s leading alcohol marketplace, Drizly which carved a unique, step-by-step growth strategy for itself and eventually, succeeded in transforming the way alcohol is bought and sold across various continents. Co-founded in 2012 by Cory Rellas and Nick Rellas, the Boston-based start-up which was one of the first few on-demand liquor delivery apps to make its way into the market,
Animal Model Market trends, Animal Model Market growth, Animal Model Market size …
Key Findings of Animal Model Market Developing Regions to Overpower Developed Ones With Regard to Demand The Asian territory is on the verge of evolving as the next big destination for animal models. This growth can be attributed to various factors such as American and European pharmaceutical companies diversifying their research activities to curtail extra expenses and save costs. Although U.S and Europe have retained their legacy in the global market, their
Cloud Computing in Healthcare Market By Deployment Model (Public- cloud deployme …
Industry Outlook and Trend Analysis The Cloud Computing in Healthcare Market was worth USD 3.05 billion in 2014 and is expected to reach approximately USD 16.25 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 20.43% during the forecast period. Cloud computing, commonly alluded to as 'the cloud', is a technique to access and store the information and projects over the internet. The cloud computing is